Lung cancer trials in Spain
273 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleStudy of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 307 worldwide
- Run by
- Xencor, Inc.
See details and how to joinNCT05433142 · EU 2024-513619-28-00 - Phase 1Taking peopleAMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 434 worldwide
- Run by
- Amgen
See details and how to joinNCT07094113 - Phase 1Taking peoplePhase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Where
- Barcelona, Madrid
- Age
- 18 years to 100 years
- People
- 162 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06562192 - Phase 3Taking peoplePhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Where
- A Coruña, Barcelona, Jaén, Madrid, San Sebastián, Zaragoza
- Age
- 18 years and over
- People
- 756 worldwide
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT06095583 - Phase 2Taking peoplePhase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419/ANV600) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL
- Where
- Barcelona
- Age
- 18 years and over
- People
- 24 worldwide
- Run by
- Vall D Hebron Institute Of Oncology
See details and how to join2023-506400-99-00 · EU 2023-506400-99-00 - Phase 2Taking peopleDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Barcelona, Madrid, Málaga, Valencia
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - Phase 1Taking peopleClinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- Where
- Badalona, Barcelona, Madrid, Santiago de Compostela, Sevilla, Valencia
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT05142189 · EU 2023-509283-14-00 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 1Taking peopleA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Where
- L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 914 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00 - Phase 1Taking peopleA Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 710 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT06179160 · EU 2023-507091-47-00 - Phase 1Taking peopleA Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
- Where
- Barcelona, Madrid, Pamplona
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06476808 · EU 2025-523067-38-01 - Phase 3Taking peopleA Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
- Where
- A Coruña, Barcelona, Donostia, Jaén, Madrid, Málaga, Sevilla, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 147 worldwide
- Run by
- Shanghai Junshi Biosciences Co. Ltd.
See details and how to join2023-507097-41-01 · EU 2023-507097-41-01 - Phase 1/2Taking peopleA Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Where
- Badalona, Barcelona, Logroño, Madrid, Pamplona, Pozuelo de Alarcón, Sevilla
- Age
- 18 years and over
- People
- 262 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07174583 · EU 2025-523438-24-00 - Phase 2Taking peopleStudy of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
- Where
- Albacete, Alicante, Barcelona, Bilbao, Elche, Jerez de la Frontera, Lugo, Madrid, Majadahonda, Málaga, Manresa, Ourense, Palma, Pamplona, Santa Cruz de Tenerife, Valencia
- Age
- 18 years and over
- People
- 37
- Run by
- Fundación GECP
See details and how to joinNCT07242547 · EU 2024-515201-26-00 - Phase 1Taking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Barcelona, Elche, Jerez de la Frontera, Madrid, Málaga, Santander
- Age
- 18 years and over
- People
- 1,006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - Phase 1/2Taking peopleA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Where
- Barcelona, Córdoba, El Palmar, Madrid, Seville, Tarragona, Valencia
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00 - Phase 2Taking peopleAutologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Where
- A Coruña, Barcelona, Castello De La Plana, Córdoba, Madrid, Málaga, Pamplona, Salamanca, Sevilla, Valencia
- Age
- 18 years to 70 years
- People
- 170 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT04614103 · EU 2024-510778-26-00 - Phase 1Taking peopleSubcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- Where
- Barcelona, Madrid, Málaga, Valencia
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Amgen
See details and how to joinNCT06598306 · EU 2024-511838-12-00 - Phase 1Taking peopleA Study of LY4175408 in Participants With Advanced Cancer
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07046923 · EU 2025-521916-20-00 - Phase 1Taking peopleA Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 52
- Run by
- Janssen Cilag International
See details and how to join2025-521535-36-00 · EU 2025-521535-36-00 - Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Where
- Badalona, Barcelona, Valencia
- Age
- 18 years and over
- People
- 182 worldwide
- Run by
- Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00 - Phase 1Taking peopleStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Where
- L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 248 worldwide
- Run by
- Calico Life Sciences LLC
See details and how to joinNCT04777994 · EU 2023-507568-38-00 - Phase 1/2Taking peopleDose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
- Where
- A Coruña, Barcelona, Girona, Málaga
- Age
- 18 years and over
- People
- 41 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT05751798 · EU 2024-514826-22-00 - Phase 2Not yet taking people in SpainPhase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
- Where
- Madrid, Palma
- Age
- 18 years and over
- People
- 158 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT07234877 · EU 2025-522985-60-00 - Phase 1Not yet taking people in SpainAn Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osimertinib or Docetaxel in Patients with Advanced NSCLC
- Where
- Barcelona, Madrid, Pozuelo de Alarcón
- Age
- 18 years and over
- People
- 40
- Run by
- TOLREMO therapeutics AG
See details and how to join2024-519071-25-00 · EU 2024-519071-25-00